90 related articles for article (PubMed ID: 2912020)
1. Phase II trial of N-methylformamide in advanced renal cancer.
Abrams JS; Tait N; Silva H; Eisenberger M; Van Echo DA; Olver IN; Aisner J
Am J Clin Oncol; 1989 Feb; 12(1):41-2. PubMed ID: 2912020
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of N-methylformamide for advanced renal cell carcinoma.
Sternberg CN; Yagoda A; Scher HI; Hollander P
Cancer Treat Rep; 1986 May; 70(5):681-2. PubMed ID: 3708620
[No Abstract] [Full Text] [Related]
3. Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study.
Rowinsky EK; Grochow LB; Hantel A; Ettinger DS; Vito BL; Donehower RC
Invest New Drugs; 1989 Nov; 7(4):317-25. PubMed ID: 2599802
[TBL] [Abstract][Full Text] [Related]
4. N-Methylformamide in advanced squamous cancer of the uterine cervix: an Eastern Cooperative Oncology Group phase II trial.
Rajdev L; Yu ZF; Wadler S; Weller E; Kahn SB; Tormey D; Skeel R; Wiernik PH
Invest New Drugs; 2001; 19(3):233-7. PubMed ID: 11561680
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of N-methylformamide (NMF, NSC 3051).
O'Dwyer PJ; Donehower M; Sigman LM; Fortner CL; Aisner J; Van Echo DA
J Clin Oncol; 1985 Jun; 3(6):853-7. PubMed ID: 4009219
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of N-methylformamide in advanced head and neck cancer.
Vogel WC; Forastiere AA; Natale RB; Takasugi BJ; Schnur G
Invest New Drugs; 1987; 5(2):203-6. PubMed ID: 3654153
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of N-methylformamide in patients with metastatic melanoma.
Eton O; Bajorin DF; Casper ES; Houghton AN
Invest New Drugs; 1991 Feb; 9(1):97-100. PubMed ID: 2026491
[TBL] [Abstract][Full Text] [Related]
8. N-methylformamide-induced hypophosphatemia.
Sternberg CN; Yagoda A
Cancer Treat Rep; 1985 Mar; 69(3):343-4. PubMed ID: 3978663
[No Abstract] [Full Text] [Related]
9. Phase I trial of N-methylformamide.
McVie JG; ten Bokkel Huinink WW; Simonetti G; Dubbelman R
Cancer Treat Rep; 1984 Apr; 68(4):607-10. PubMed ID: 6325001
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity.
Rowinsky EK; Noe DA; Orr DW; Grochow LB; Ettinger DS; Donehower RC
J Natl Cancer Inst; 1988 Jul; 80(9):671-8. PubMed ID: 3373556
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of N-methylformamide in patients with advanced colorectal carcinoma.
Tauer K; Kemeny N; Cheng E; Hollander P; Geller N
Cancer Treat Rep; 1986 Jun; 70(6):813-4. PubMed ID: 3524831
[No Abstract] [Full Text] [Related]
12. Phase I study of N-methylformamide in patients with advanced cancer.
Ettinger DS; Orr DW; Rice AP; Donehower RC
Cancer Treat Rep; 1985 May; 69(5):489-93. PubMed ID: 4005871
[TBL] [Abstract][Full Text] [Related]
13. Toxicity of oral N-methylformamide in three phase II trials: a report from the National Cancer Institute of Canada Clinical Trials Group.
Eisenhauer EA; Weinerman BH; Kerr I; Quirt I
Cancer Treat Rep; 1986 Jul; 70(7):881-3. PubMed ID: 3719579
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
Weinerman BH; Eisenhauer EA; Besner JG; Coppin CM; Stewart D; Band PR
Cancer Treat Rep; 1986 Jun; 70(6):751-4. PubMed ID: 3524824
[TBL] [Abstract][Full Text] [Related]
15. Phase II evaluation of amonafide in renal cell carcinoma. A Southwest Oncology Group study.
Higano CS; Goodman P; Craig JB; Kish JA; Rivkin SE; Wolf M; Crawford ED
Invest New Drugs; 1991 Nov; 9(4):361-3. PubMed ID: 1804814
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study.
Shevrin DH; Lad TE; Kilton LJ; Cobleigh MA; Blough RR; Weidner LL; Vogelzang NJ
Invest New Drugs; 1989 Jul; 7(2-3):251-3. PubMed ID: 2477345
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
Van Veldhuizen PJ; Faulkner JR; Lara PN; Gumerlock PH; Goodwin JW; Dakhil SR; Gross HM; Flanigan RC; Crawford ED;
Cancer Chemother Pharmacol; 2005 Jul; 56(1):39-45. PubMed ID: 15791454
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of N-methylformamide in patients with advanced colorectal cancer.
Tchekmedyian NS; Kaplan RS; Eisenberger M; Abrams J; Van Echo D
Cancer Treat Rep; 1987 May; 71(5):541-2. PubMed ID: 3567980
[No Abstract] [Full Text] [Related]
20. Phase II study on oral N-methylformamide in metastatic colorectal cancer.
Planting AS; Klijn JG; Verweij J; Stoter G
Cancer Treat Rep; 1987 Dec; 71(12):1293-4. PubMed ID: 3690540
[No Abstract] [Full Text] [Related]
[Next] [New Search]
